Unmasking cancer
cell camouflage
with multifunctional
fusion proteins
Unmasking
cancer cell
camouflage
cancer cell
camouflage
KAHR develops customizable immuno-recruitment cancer drug candidates
that utilize various methods to synergistically disable cancer defenses and activate
a targeted response involving both innate and adaptive immunity
that utilize various methods to synergistically disable cancer defenses and activate
a targeted response involving both innate and adaptive immunity
Synergistic recruitment and activation of innate
and adaptive anti-cancer immunity
with Multifunctional Immuno-Recruitment Proteins (MIRP)
SIRPα
- Binds CD47 on tumor cells
- Prevents “don’t eat me” signals
- Phagocytes ingest tumor cells
41BBL
- Binds 41BB receptor on T cells
- T-cell activation and proliferation
- T-cell induced tumor killing
Unique Features
Multi-functional mechanism –
synergistic innate and
adaptive immunity
Flexibility allows target
driven customization
for increased activity
Tumor localized effect –
avoiding systemic toxicity
Suitable for solid and
hematological
malignancies
Get in Touch
KAHR Dam HaMacbim St 28, POB 9 Modi'in Makabim-Re'ut 7178594, Israel T. +972.73.7969196 [email protected]